Picture of Immuron logo

IMC — Immuron News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Brief: Immuron US DoD Naval Medical Research Center Receives Feedback On on IND Application For New Campylobacter ETEC Therapeutic

July 26 (Reuters) - Immuron Ltd  IMC.AX :
    * IMMURON US DOD NAVAL MEDICAL RESEARCH CENTER RECEIVES
FEEDBACK
ON IND APPLICATION FOR NEW CAMPYLOBACTER ETEC THERAPEUTIC
    * IMMURON LTD - RECEIVED FEEDBACK FROM U.S. FDA AFTER REVIEW
OF
IND FOR A NEW ORAL THERAPEUTIC TARGETING CAMPYLOBACTER AND ETEC
    * IMMURON - AGENCY  SPECIFIED IND DOES NOT CONTAIN
SUFFICIENT
INFORMATION REQUIRED UNDER 21 CFR 312.23 TO ASSESS RISK TO
SUBJECTS IN PROPOSED STUDIES
    * IMMURON - IND PLACED ON CLINICAL HOLD UNTIL FDA HAVE
RECEIVED,
REVIEWED RESPONSE FROM NMRC JUSTIFYING DOSING, SAFETY
MONITORING, RISK MITIGATION PLAN

Source text for Eikon:  ID:nGNX9nH9sr 
Further company coverage:  IMC.AX 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Immuron

See all news